sorafenib has been researched along with guanine in 9 studies
| Studies (sorafenib) | Trials (sorafenib) | Recent Studies (post-2010) (sorafenib) | Studies (guanine) | Trials (guanine) | Recent Studies (post-2010) (guanine) |
|---|---|---|---|---|---|
| 6,520 | 730 | 5,251 | 16,278 | 822 | 4,809 |
| Protein | Taxonomy | sorafenib (IC50) | guanine (IC50) |
|---|---|---|---|
| Purine nucleoside phosphorylase | Homo sapiens (human) | 5 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (11.11) | 29.6817 |
| 2010's | 8 (88.89) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hanna, N | 1 |
| Bernard, S; Chiu, M; Davies, JM; Dees, EC; Dhruva, NS; Hayes, DN; Hilbun, LR; Ivanova, A; Keller, K; Kim, WY; Socinski, MA; Stinchcombe, TE; Walko, CM | 1 |
| Bareford, MD; Burow, ME; Cruickshanks, N; Dent, P; Eulitt, P; Fisher, PB; Grant, S; Hamed, HA; Hubbard, N; Moran, RG; Nephew, KP; Park, MA; Tang, Y; Tye, G; Yacoub, A | 1 |
| Bareford, MD; Burow, ME; Cruickshanks, N; Dent, P; Fisher, PB; Grant, S; Hamed, HA; Moran, RG; Nephew, KP; Tang, Y | 1 |
| Allegood, J; Bareford, MD; Cruickshanks, N; Dent, P; Grant, S; Hamed, HA; Ogretmen, B; Park, MA; Poklepovic, A; Spiegel, S | 1 |
| Chen, J; Chen, L; Jiang, Y; Li, C; Li, Y; Ma, Y | 1 |
| Barrington, S; Cane, P; Dunn, JT; Lal, R; Landau, D; Lang-Lazdunski, L; McLennan, B; Papa, S; Popat, S; Prevost, AT; Shah, R; Spicer, J; Viney, Z | 1 |
| D'Angelo, S; De Cristofano, R; Secondulfo, M; Sorrentino, P | 1 |
| Hu, YQ; Meyer, S; Moyo, H; Tomlinson, C; Waterhouse, C | 1 |
3 trial(s) available for sorafenib and guanine
| Article | Year |
|---|---|
Second-line treatment of non-small cell lung cancer: big targets, small progress; small targets, big progress?
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase II as Topic; Docetaxel; Female; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Niacinamide; Pemetrexed; Phenylurea Compounds; Piperidines; Probability; Prognosis; Pyridines; Quinazolines; Randomized Controlled Trials as Topic; Risk Assessment; Sorafenib; Survival Analysis; Taxoids; Treatment Outcome | 2006 |
A phase I trial of sorafenib combined with cisplatin/etoposide or carboplatin/pemetrexed in refractory solid tumor patients.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Cisplatin; Etoposide; Female; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Niacinamide; Pemetrexed; Phenylurea Compounds; Pyridines; Sorafenib; Treatment Outcome | 2011 |
Phase 2 study of sorafenib in malignant mesothelioma previously treated with platinum-containing chemotherapy.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Glutamates; Guanine; Humans; Male; Mesothelioma; Middle Aged; Neoplasm Staging; Niacinamide; Pemetrexed; Phenylurea Compounds; Platinum; Pleural Neoplasms; Prognosis; Protein Kinase Inhibitors; Salvage Therapy; Sorafenib; Survival Rate | 2013 |
6 other study(ies) available for sorafenib and guanine
| Article | Year |
|---|---|
Sorafenib enhances pemetrexed cytotoxicity through an autophagy-dependent mechanism in cancer cells.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Autophagy; Benzenesulfonates; Cell Line, Tumor; Drug Synergism; Female; Glutamates; Guanine; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasms; Niacinamide; Pemetrexed; Phenylurea Compounds; Pyridines; Sorafenib; Tissue Distribution | 2011 |
Sorafenib enhances pemetrexed cytotoxicity through an autophagy-dependent mechanism in cancer cells.
Topics: Animals; Antineoplastic Agents; Autophagy; Benzenesulfonates; Cell Line, Tumor; Dose-Response Relationship, Drug; Drug Synergism; Gene Expression Regulation, Neoplastic; Glutamates; Guanine; Humans; Liver Neoplasms; Mice; Neoplasm Transplantation; Neoplasms; Neovascularization, Pathologic; Niacinamide; Pemetrexed; Phenylurea Compounds; Phosphorylation; Protein Kinase Inhibitors; Pyridines; Sorafenib | 2011 |
Sorafenib and pemetrexed toxicity in cancer cells is mediated via SRC-ERK signaling.
Topics: Antineoplastic Agents; Autophagy; Benzenesulfonates; Breast Neoplasms; Cell Line, Tumor; Drug Synergism; Endosomes; Enzyme Activation; Extracellular Signal-Regulated MAP Kinases; Female; Gene Knockdown Techniques; Glutamates; Guanine; Humans; MAP Kinase Signaling System; Niacinamide; Pemetrexed; Phenylurea Compounds; Protein Phosphatase 2; Pyridines; Receptor, Platelet-Derived Growth Factor beta; RNA Interference; Sorafenib; src-Family Kinases | 2012 |
The inhibition of the pemetrexed-activated MAPK pathway via sorafenib is involved in the synergistic mechanism of sorafenib subsequent potentiation of pemetrexed cytotoxicity in EGFR TKI-resistant cell lines.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Survival; Drug Resistance, Neoplasm; Drug Synergism; Drug Therapy, Combination; Enzyme Inhibitors; ErbB Receptors; Glutamates; Guanine; Humans; Lung Neoplasms; MAP Kinase Signaling System; Niacinamide; Pemetrexed; Phenylurea Compounds; Protein-Tyrosine Kinases; Pyridines; Sorafenib | 2012 |
Sorafenib and entecavir: the dioscuri of treatment for advanced hepatocellular carcinoma?
Topics: Aged; Antineoplastic Agents; Antiviral Agents; Carcinoma, Hepatocellular; Female; Guanine; Hepatitis B; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Sorafenib; Time Factors; Treatment Outcome | 2013 |
How patent law reform can improve affordability and accessibility of medicines in South Africa: Four medicine case studies.
Topics: Antineoplastic Agents; Antiviral Agents; Costs and Cost Analysis; Drug Costs; Drug Industry; Erlotinib Hydrochloride; Guanine; Health Services Accessibility; Humans; Immunologic Factors; Lenalidomide; Patents as Topic; Pharmaceutical Preparations; Sorafenib; South Africa | 2019 |